Symbols / CCCC
CCCC Chart
About
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 clinical trials targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting BRAF V600 mutant that is in Phase 1/2 clinical trials to treat melanoma, colorectal cancer, and other solid malignancies; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor with an L858R mutation in non-small cell lung cancer. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; Merck KGaA; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 231.63M |
| Enterprise Value | 101.20M | Income | -119.08M | Sales | 30.11M |
| Book/sh | 2.08 | Cash/sh | 1.98 | Dividend Yield | — |
| Payout | 0.00% | Employees | 110 | IPO | — |
| P/E | — | Forward P/E | -1.86 | PEG | — |
| P/S | 7.69 | P/B | 1.15 | P/C | — |
| EV/EBITDA | -0.86 | EV/Sales | 3.36 | Quick Ratio | 5.52 |
| Current Ratio | 5.75 | Debt/Eq | 39.81 | LT Debt/Eq | — |
| EPS (ttm) | -1.67 | EPS next Y | -1.29 | EPS Growth | — |
| Revenue Growth | -26.90% | Earnings | 2026-02-26 | ROA | -23.20% |
| ROE | -59.98% | ROIC | — | Gross Margin | -271.23% |
| Oper. Margin | -210.86% | Profit Margin | 0.00% | Shs Outstand | 96.91M |
| Shs Float | 66.11M | Short Float | 7.86% | Short Ratio | 4.70 |
| Short Interest | — | 52W High | 3.65 | 52W Low | 1.08 |
| Beta | 2.95 | Avg Volume | 1.51M | Volume | 6.06M |
| Target Price | $11.29 | Recom | Strong_buy | Prev Close | $2.30 |
| Price | $2.39 | Change | 3.91% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$11.29
Mean price target
2. Current target
$2.83
Latest analyst target
3. DCF / Fair value
$-10.21
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.83
Low
$5.00
High
$30.00
Mean
$11.29
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-23 | main | Brookline Capital | Buy → Buy | $30 |
| 2025-12-17 | main | Barclays | Overweight → Overweight | $5 |
| 2025-12-02 | init | TD Cowen | — → Buy | — |
| 2025-09-23 | main | Wells Fargo | Overweight → Overweight | $10 |
| 2025-09-23 | main | Barclays | Overweight → Overweight | $10 |
| 2025-09-22 | reit | Stephens & Co. | Overweight → Overweight | $6 |
| 2025-09-17 | init | Barclays | — → Overweight | $8 |
| 2025-09-15 | up | Stephens & Co. | Equal-Weight → Overweight | $6 |
| 2025-09-04 | init | Guggenheim | — → Buy | $8 |
| 2024-12-19 | up | Wells Fargo | Equal-Weight → Overweight | $12 |
| 2024-11-18 | init | Stephens & Co. | — → Equal-Weight | $4 |
| 2024-08-06 | reit | BMO Capital | Outperform → Outperform | $20 |
| 2024-05-09 | main | Wells Fargo | Equal-Weight → Equal-Weight | $8 |
| 2024-05-09 | main | Stifel | Buy → Buy | $14 |
| 2024-02-26 | main | Morgan Stanley | Equal-Weight → Equal-Weight | $8 |
| 2024-02-23 | reit | Stifel | Buy → Buy | $13 |
| 2024-01-29 | up | JP Morgan | Underweight → Neutral | $6 |
| 2023-12-13 | up | Stifel | Hold → Buy | $12 |
| 2023-11-06 | up | Morgan Stanley | Underweight → Equal-Weight | $1 |
| 2023-11-03 | main | BMO Capital | Outperform → Outperform | $16 |
- Investor watch: C4 Therapeutics fireside chats in Boston and Miami - Stock Titan Mon, 23 Feb 2026 12
- $CCCC stock is up 9% today. Here's what we see in our data. - Quiver Quantitative hu, 19 Feb 2026 19
- Brookline Capital Raises Price Target for C4 Therapeutics (CCCC) to $30 | CCCC Stock News - GuruFocus Mon, 23 Feb 2026 17
- Strong Analyst Confidence in C4 Therapeutics (CCCC)’s Cemsidomide Drives 270% Upside Potential - Yahoo Finance Fri, 20 Feb 2026 21
- New oral myeloma drug from C4 Therapeutics enters Phase 2 test - Stock Titan Mon, 23 Feb 2026 12
- Brookline Raises C4 Therapeutics Price Target Amid Trial Confidence​ - StocksToTrade ue, 24 Feb 2026 17
- Insufficient Growth At C4 Therapeutics, Inc. (NASDAQ:CCCC) Hampers Share Price - simplywall.st Wed, 17 Dec 2025 08
- TD Cowen Initiates Coverage of C4 Therapeutics (CCCC) with Buy Recommendation - Nasdaq ue, 02 Dec 2025 08
- Brookline’s Bold Move Boosts C4 Therapeutics Stock Prospects - timothysykes.com ue, 24 Feb 2026 16
- Brookline Capital raises C4 Therapeutics stock price target on trial progress - Investing.com Mon, 23 Feb 2026 17
- Is C4 Therapeutics (CCCC) One of the Best Biotech Penny Stocks to Buy According to Analysts? - Yahoo Finance Wed, 31 Dec 2025 08
- CCCC Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan Mon, 23 Feb 2026 17
- Barclays Raises Price Target for C4 Therapeutics (CCCC) in Lates - GuruFocus ue, 23 Sep 2025 07
- C4 Therapeutics, Inc. (CCCC): A Bull Case Theory - Yahoo Finance Mon, 02 Feb 2026 08
- $125M Upfront — C4 Therapeutics Prices Offering to Fund Cemsidomide Trials; May Reach $349.7M - Stock Titan hu, 16 Oct 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 700000 | — | — | Stock Award(Grant) at price 0.00 per share. | HIRSCH ANDREW | Chief Executive Officer | — | 2026-02-13 00:00:00 | D |
| 1 | 102125 | nan | — | — | HIRSCH ANDREW | Chief Executive Officer | — | 2026-02-13 00:00:00 | D |
| 2 | 240000 | — | — | Stock Award(Grant) at price 0.00 per share. | REYNO LEONARD | Officer | — | 2026-02-13 00:00:00 | D |
| 3 | 30950 | nan | — | — | REYNO LEONARD | Officer | — | 2026-02-13 00:00:00 | D |
| 4 | 200000 | — | — | Stock Award(Grant) at price 0.00 per share. | SCHICK KELLY | Officer | — | 2026-02-13 00:00:00 | D |
| 5 | 25950 | nan | — | — | SCHICK KELLY | Officer | — | 2026-02-13 00:00:00 | D |
| 6 | 200000 | — | — | Stock Award(Grant) at price 0.00 per share. | BOYLE SCOTT N | Officer | — | 2026-02-13 00:00:00 | D |
| 7 | 25950 | nan | — | — | BOYLE SCOTT N | Officer | — | 2026-02-13 00:00:00 | D |
| 8 | 240000 | — | — | Stock Award(Grant) at price 0.00 per share. | ADAMS KENDRA | Chief Financial Officer | — | 2026-02-13 00:00:00 | D |
| 9 | 34700 | nan | — | — | ADAMS KENDRA | Chief Financial Officer | — | 2026-02-13 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -511.77K | -130.41K | 0.00 | 0.00 |
| TaxRateForCalcs | 0.21 | 0.21 | 0.00 | 0.00 |
| NormalizedEBITDA | -100.93M | -127.34M | -124.28M | -80.25M |
| TotalUnusualItems | -2.44M | -621.00K | 0.00 | |
| TotalUnusualItemsExcludingGoodwill | -2.44M | -621.00K | 0.00 | |
| NetIncomeFromContinuingOperationNetMinorityInterest | -105.32M | -132.49M | -128.18M | -83.89M |
| ReconciledDepreciation | 1.82M | 1.88M | 1.68M | 1.49M |
| EBITDA | -103.37M | -127.96M | -124.28M | -80.25M |
| EBIT | -105.19M | -129.84M | -125.96M | -81.75M |
| NetInterestIncome | 14.43M | 8.44M | 1.36M | -1.76M |
| InterestExpense | 0.00 | 1.37M | 2.22M | 2.15M |
| InterestIncome | 14.43M | 9.81M | 3.58M | 387.00K |
| NormalizedIncome | -103.39M | -132.00M | -128.18M | -83.89M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -105.32M | -132.49M | -128.18M | -83.89M |
| TotalExpenses | 152.76M | 159.79M | 160.63M | 127.92M |
| TotalOperatingIncomeAsReported | -119.61M | -139.03M | -129.53M | -82.13M |
| DilutedAverageShares | 69.37M | 49.64M | 48.86M | 46.04M |
| BasicAverageShares | 69.37M | 49.64M | 48.86M | 46.04M |
| DilutedEPS | -1.52 | -2.67 | -2.62 | -1.82 |
| BasicEPS | -1.52 | -2.67 | -2.62 | -1.82 |
| DilutedNIAvailtoComStockholders | -105.32M | -132.49M | -128.18M | -83.89M |
| NetIncomeCommonStockholders | -105.32M | -132.49M | -128.18M | -83.89M |
| NetIncome | -105.32M | -132.49M | -128.18M | -83.89M |
| NetIncomeIncludingNoncontrollingInterests | -105.32M | -132.49M | -128.18M | -83.89M |
| NetIncomeContinuousOperations | -105.32M | -132.49M | -128.18M | -83.89M |
| TaxProvision | 131.00K | 1.28M | 0.00 | 0.00 |
| PretaxIncome | -105.19M | -131.21M | -128.18M | -83.89M |
| OtherIncomeExpense | -2.44M | -621.00K | ||
| SpecialIncomeCharges | -2.44M | -621.00K | 0.00 | |
| OtherSpecialCharges | 621.00K | |||
| RestructuringAndMergernAcquisition | 2.44M | 0.00 | ||
| NetNonOperatingInterestIncomeExpense | 14.43M | 8.44M | 1.36M | -1.76M |
| InterestExpenseNonOperating | 0.00 | 1.37M | 2.22M | 2.15M |
| InterestIncomeNonOperating | 14.43M | 9.81M | 3.58M | 387.00K |
| OperatingIncome | -117.18M | -139.03M | -129.53M | -82.13M |
| OperatingExpense | 152.76M | 159.79M | 160.63M | 127.92M |
| ResearchAndDevelopment | 110.64M | 117.71M | 117.84M | 94.67M |
| SellingGeneralAndAdministration | 42.12M | 42.08M | 42.79M | 33.25M |
| GeneralAndAdministrativeExpense | 42.12M | 42.08M | 42.79M | 33.25M |
| OtherGandA | 10.85M | 11.84M | 12.24M | 10.24M |
| SalariesAndWages | 31.28M | 30.24M | 30.55M | 23.01M |
| TotalRevenue | 35.58M | 20.76M | 31.10M | 45.78M |
| OperatingRevenue | 35.58M | 20.76M | 31.10M | 45.78M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 70.63M | 60.47M | 48.97M | 48.69M |
| ShareIssued | 70.63M | 60.47M | 48.97M | 48.69M |
| TotalDebt | 65.76M | 70.98M | 87.15M | 42.88M |
| TangibleBookValue | 215.99M | 246.11M | 289.23M | 389.61M |
| InvestedCapital | 215.99M | 246.11M | 300.72M | 400.37M |
| WorkingCapital | 212.59M | 228.42M | 243.01M | 274.44M |
| NetTangibleAssets | 215.99M | 246.11M | 289.23M | 389.61M |
| CapitalLeaseObligations | 65.76M | 70.98M | 75.67M | 32.11M |
| CommonStockEquity | 215.99M | 246.11M | 289.23M | 389.61M |
| TotalCapitalization | 215.99M | 246.11M | 298.43M | 400.37M |
| TotalEquityGrossMinorityInterest | 215.99M | 246.11M | 289.23M | 389.61M |
| StockholdersEquity | 215.99M | 246.11M | 289.23M | 389.61M |
| GainsLossesNotAffectingRetainedEarnings | 53.00K | -127.00K | -4.14M | -775.00K |
| OtherEquityAdjustments | 53.00K | -127.00K | -4.14M | -775.00K |
| RetainedEarnings | -633.70M | -528.38M | -395.89M | -267.71M |
| AdditionalPaidInCapital | 849.62M | 774.62M | 689.26M | 658.09M |
| CapitalStock | 7.00K | 6.00K | 5.00K | 5.00K |
| CommonStock | 7.00K | 6.00K | 5.00K | 5.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 133.62M | 130.34M | 141.61M | 117.16M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 88.44M | 87.57M | 97.06M | 65.91M |
| NonCurrentDeferredLiabilities | 28.46M | 21.81M | 16.89M | 24.37M |
| NonCurrentDeferredRevenue | 28.46M | 21.81M | 16.89M | 24.37M |
| LongTermDebtAndCapitalLeaseObligation | 59.98M | 65.76M | 80.17M | 41.55M |
| LongTermCapitalLeaseObligation | 59.98M | 65.76M | 70.97M | 30.78M |
| LongTermDebt | 9.20M | 10.77M | ||
| CurrentLiabilities | 45.18M | 42.77M | 44.55M | 51.25M |
| OtherCurrentLiabilities | 1.87M | 2.04M | 3.11M | 413.00K |
| CurrentDeferredLiabilities | 18.71M | 15.47M | 16.62M | 31.80M |
| CurrentDeferredRevenue | 18.71M | 15.47M | 16.62M | 31.80M |
| CurrentDebtAndCapitalLeaseObligation | 5.77M | 5.22M | 6.99M | 1.33M |
| CurrentCapitalLeaseObligation | 5.77M | 5.22M | 4.70M | 1.33M |
| CurrentDebt | 2.29M | |||
| OtherCurrentBorrowings | 2.29M | |||
| PensionandOtherPostRetirementBenefitPlansCurrent | 7.43M | 7.34M | 6.83M | 5.08M |
| PayablesAndAccruedExpenses | 11.39M | 12.69M | 11.00M | 12.62M |
| CurrentAccruedExpenses | 10.06M | 11.24M | 9.82M | 8.11M |
| Payables | 1.33M | 1.45M | 1.17M | 4.51M |
| AccountsPayable | 1.33M | 1.45M | 1.17M | 4.51M |
| TotalAssets | 349.60M | 376.45M | 430.84M | 506.76M |
| TotalNonCurrentAssets | 91.83M | 105.26M | 143.28M | 181.08M |
| OtherNonCurrentAssets | 6.10M | 6.17M | 4.80M | 3.82M |
| InvestmentsAndAdvances | 22.36M | 28.01M | 60.96M | 142.20M |
| InvestmentinFinancialAssets | 22.36M | 28.01M | 60.96M | 142.20M |
| AvailableForSaleSecurities | 22.36M | 28.01M | 60.96M | 142.20M |
| NetPPE | 63.38M | 71.09M | 77.52M | 35.05M |
| AccumulatedDepreciation | -9.24M | -7.76M | -8.12M | -6.92M |
| GrossPPE | 72.61M | 78.85M | 85.64M | 41.97M |
| Leases | 4.71M | 4.71M | 4.68M | 541.00K |
| ConstructionInProgress | 0.00 | 183.00K | 0.00 | |
| OtherProperties | 65.75M | 72.00M | 78.87M | 40.22M |
| MachineryFurnitureEquipment | 2.15M | 2.14M | 1.90M | 1.21M |
| BuildingsAndImprovements | 31.95M | |||
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 257.77M | 271.19M | 287.56M | 325.69M |
| OtherCurrentAssets | 9.76M | 5.71M | 9.93M | 10.69M |
| PrepaidAssets | 10.69M | |||
| Receivables | 3.10M | 11.80M | 1.47M | 5.72M |
| AccountsReceivable | 3.10M | 11.80M | 1.47M | 5.72M |
| CashCashEquivalentsAndShortTermInvestments | 244.90M | 253.68M | 276.15M | 309.28M |
| OtherShortTermInvestments | 189.41M | 127.09M | 246.40M | 233.16M |
| CashAndCashEquivalents | 55.50M | 126.59M | 29.75M | 76.12M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -65.34M | -108.55M | -111.44M | -88.24M |
| RepurchaseOfCapitalStock | -194.00K | -110.00K | 0.00 | 0.00 |
| RepaymentOfDebt | 0.00 | -12.50M | 0.00 | |
| IssuanceOfDebt | 0.00 | |||
| IssuanceOfCapitalStock | 44.37M | 57.67M | 0.00 | 169.47M |
| CapitalExpenditure | -180.00K | -1.71M | -5.50M | -1.28M |
| InterestPaidSupplementalData | 0.00 | 990.00K | 1.62M | 1.31M |
| IncomeTaxPaidSupplementalData | 0.00 | 1.00M | 0.00 | 0.00 |
| EndCashPosition | 58.94M | 130.03M | 33.03M | 79.40M |
| BeginningCashPosition | 130.03M | 33.03M | 79.40M | 184.30M |
| ChangesInCash | -71.09M | 97.00M | -46.37M | -104.90M |
| FinancingCashFlow | 45.34M | 45.49M | 1.15M | 171.40M |
| CashFlowFromContinuingFinancingActivities | 45.34M | 45.49M | 1.15M | 171.40M |
| NetOtherFinancingCharges | 382.00K | 368.00K | 370.00K | -395.00K |
| ProceedsFromStockOptionExercised | 778.00K | 58.00K | 777.00K | 2.33M |
| NetCommonStockIssuance | 44.18M | 57.56M | 0.00 | 169.47M |
| CommonStockPayments | -194.00K | -110.00K | 0.00 | 0.00 |
| CommonStockIssuance | 44.37M | 57.67M | 0.00 | 169.47M |
| NetIssuancePaymentsOfDebt | 0.00 | -12.50M | 0.00 | 0.00 |
| NetLongTermDebtIssuance | 0.00 | -12.50M | 0.00 | 0.00 |
| LongTermDebtPayments | 0.00 | -12.50M | 0.00 | |
| LongTermDebtIssuance | 0.00 | |||
| InvestingCashFlow | -51.27M | 158.35M | 58.42M | -189.34M |
| CashFlowFromContinuingInvestingActivities | -51.27M | 158.35M | 58.42M | -189.34M |
| NetInvestmentPurchaseAndSale | -51.09M | 160.06M | 63.92M | -188.06M |
| SaleOfInvestment | 233.23M | 289.95M | 283.44M | 349.68M |
| PurchaseOfInvestment | -284.32M | -129.90M | -219.53M | -537.74M |
| NetPPEPurchaseAndSale | -180.00K | -1.71M | -5.50M | -1.28M |
| SaleOfPPE | 0.00 | |||
| PurchaseOfPPE | -180.00K | -1.71M | -5.50M | -1.28M |
| OperatingCashFlow | -65.16M | -106.84M | -105.94M | -86.97M |
| CashFlowFromContinuingOperatingActivities | -65.16M | -106.84M | -105.94M | -86.97M |
| ChangeInWorkingCapital | 7.65M | -6.94M | -16.78M | -30.09M |
| ChangeInOtherWorkingCapital | 9.88M | 3.77M | -22.65M | -25.05M |
| ChangeInOtherCurrentLiabilities | -5.22M | -4.70M | -507.00K | -888.00K |
| ChangeInPayablesAndAccruedExpense | -1.39M | 1.59M | 1.75M | 3.20M |
| ChangeInAccruedExpense | -1.27M | 1.32M | 5.08M | 4.38M |
| ChangeInPayable | -119.00K | 273.00K | -3.33M | -1.18M |
| ChangeInAccountPayable | -119.00K | 273.00K | -3.33M | -1.18M |
| ChangeInPrepaidAssets | -4.33M | 2.72M | 388.00K | -6.12M |
| ChangeInReceivables | 8.70M | -10.33M | 4.24M | -1.23M |
| ChangesInAccountReceivables | 8.70M | -10.33M | 4.24M | -1.23M |
| OtherNonCashItems | 6.00K | 482.00K | 713.00K | 719.00K |
| StockBasedCompensation | 29.66M | 27.23M | 30.02M | 21.51M |
| AssetImpairmentCharge | 6.42M | 6.16M | 5.90M | 1.42M |
| AmortizationOfSecurities | -5.40M | -3.78M | 714.00K | 1.88M |
| DepreciationAmortizationDepletion | 1.82M | 1.88M | 1.68M | 1.49M |
| DepreciationAndAmortization | 1.82M | 1.88M | 1.68M | 1.49M |
| Depreciation | 1.68M | 1.49M | ||
| OperatingGainsLosses | 621.00K | |||
| GainLossOnSaleOfPPE | 0.00 | |||
| NetIncomeFromContinuingOperations | -105.32M | -132.49M | -128.18M | -83.89M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for CCCC
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|